Replimune Group (NASDAQ:REPL) Price Target Raised to $6.00 at Wedbush

Replimune Group (NASDAQ:REPL) had its price objective lifted by Wedbush from $2.00 to $6.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Wedbush’s price objective would indicate a potential downside of 34.61% from the stock’s current price.

Several other brokerages also recently commented on REPL. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Seven investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $4.88.

Replimune Group Trading Up 5.6%

Shares of NASDAQ:REPL traded up $0.49 during midday trading on Monday, hitting $9.18. 5,288,154 shares of the stock traded hands, compared to its average volume of 4,778,363. The stock has a market capitalization of $757.66 million, a PE ratio of -2.68 and a beta of 0.88. The business’s 50 day moving average is $4.88 and its two-hundred day moving average is $7.25. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a one year low of $1.50 and a one year high of $13.24.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 6,500 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the transaction, the insider directly owned 151,588 shares of the company’s stock, valued at $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. International Assets Investment Management LLC bought a new position in Replimune Group in the fourth quarter worth about $29,000. CWM LLC increased its stake in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares in the last quarter. Essential Partners LLC increased its stake in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Replimune Group during the second quarter valued at approximately $69,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.